Skip to main content


Figure 6 | Molecular Brain

Figure 6

From: Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1

Figure 6

Changes in the expression of mGlu1α or mGlu5 receptors following treatments with Ro0711401 or JNJ16259685. Immunohistochemical analysis of mGlu1α and mGlu5 receptors in cerebellar serial sections of symptomatic SCA1 mice 6 days following a single s.c. injection of vehicle or Ro0711401 (10 mg/kg) is shown in (A) and (B), respectively. Note the disappearance of mGlu5 receptors from Purkinje cells after treatment with Ro0711401. Immunoblot analysis of mGlu5 receptors in wild-type mice treated acutely or repeatedly with JNJ16259685 (2.5 mg/kg) is shown in (C). Control mice were treated daily i.p. with vehicle for 6 days. The group of mice indicated as “single injection of JNJ16259685” received a 6-day treatment of vehicle followed by a single administration of JNJ16259685. The third group of mice received daily injections of JNJ16259685 for 6 days. A representative immunoblot of mGlu5 receptor is shown. Densitometric values are means ± S.E.M. of 5 mice per group. *p < 0.05 vs. mice treated with vehicle (One-way ANOVA + Fisher’s LSD). F(2,12) = 13.124. Immunohistochemical analysis of mGlu5 receptors in the cerebellum of the same mice is shown in (D).

Back to article page